European Green Light for New Treatment in Adolescents
- The European Medicines Agency (EMA) issued a positive opinion on August 25, 2024, recommending the approval of Winlevi (clascoterone cream 1%) for the treatment of facial acne in...
- Acne vulgaris is a common skin condition characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, and sometimes nodules and cysts.
- Customary acne treatments frequently enough target inflammation or bacterial growth.
“`html
EMA Backs Winlevi for Adolescent Acne Treatment in Europe
Table of Contents
The European Medicines Agency (EMA) issued a positive opinion on August 25, 2024, recommending the approval of Winlevi (clascoterone cream 1%) for the treatment of facial acne in adolescents aged 12 adn older, as well as adults. This expands access to a non-steroidal anti-androgen treatment previously available in the United States, Canada, the United Kingdom, Australia, Malaysia, and Singapore.
Understanding Acne: The Role of Androgens
Acne vulgaris is a common skin condition characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, and sometimes nodules and cysts. A key driver of acne development is the overproduction of sebum (oil) in the skin, frequently enough triggered by androgen hormones. Androgens, such as testosterone, stimulate the sebaceous glands, leading to increased oil production.This excess sebum, combined with dead skin cells, can clog pores and create an surroundings conducive to the growth of Cutibacterium acnes (formerly Propionibacterium acnes), a bacterium associated with acne inflammation.
Customary acne treatments frequently enough target inflammation or bacterial growth. Winlevi offers a different approach by directly addressing the androgen pathway in the skin.
How Winlevi Works: A Topical Anti-Androgen
Winlevi contains clascoterone, a first-in-class topical anti-androgen. It effectively works by blocking the androgen receptor in the skin, reducing the effects of androgens on sebaceous glands. This leads to decreased sebum production and, consequently, fewer clogged pores and reduced acne inflammation. Unlike systemic anti-androgen medications (taken orally), Winlevi is applied directly to the skin, minimizing systemic absorption and potential side effects.
clinical trials have demonstrated Winlevi’s efficacy in reducing acne lesions.A Phase 3 clinical trial published in the Journal of the American Academy of Dermatology showed that Winlevi considerably reduced inflammatory acne lesions compared to a placebo after 12 weeks of treatment.
Expert Opinion and Future Outlook
The EMA’s favorable opinion has been welcomed by dermatologists. professor Brigitte Dréno,a leading expert in dermato-oncology and former president of the French Dermatology Society,described the decision as “a real progress.” She stated, “We were waiting for an innovation like this: a well-tolerated, effective and safe topic anti-androgen for adolescents.It will be a precious asset for our therapeutic options.”
(Cosmo Communiqué).
However, the path to market availability isn’t complete. In France, Winlevi still requires a positive opinion from the Haute Autorité de Santé (HAS), the French health authority, before it can be marketed. The HAS evaluates the medical,economic,and social value of new medications.